Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD
May 16th 2024The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]
The Promising Future of Gene Therapy in Treating Neurological Diseases: Michael Kaplitt, MD, PhD
May 15th 2024The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]
Insights Into Nasal Pathways for Brain Protein Sampling and Treatment Delivery: Mony de Leon, EdD
May 15th 2024The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]
Open-Label Data vs Real-World Data for Anti-CD20 Therapies in Multiple Sclerosis
May 14th 2024Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.
Downstream Impacts of Undiagnosed Lennox-Gastaut Syndrome: Scott Perry, MD
May 14th 2024The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center detailed some of consequences of undiagnosed or misdiagnosed LGS, and how it may impact long-term care for eligible patients. [WATCH TIME: 4 minutes]
Amyloid Cascade Hypothesis of Alzheimer’s Disease
May 13th 2024Panelists delve into the amyloid cascade hypothesis of Alzheimer's disease and the ongoing debate surrounding it, discussing the presence and potential roles of Aβ monomers, oligomers, protofibrils, and amyloid plaques in patients with Alzheimer's disease.
Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease
May 13th 2024The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.
Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN
May 13th 2024The director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]
Understanding the Impact of Data Analysis on Preventive Migraine Treatment: Jessica Ailani, MD
May 7th 2024The director of the MedStar Georgetown Headache Center discussed the importance of maintaining hope and providing understanding of patients' frustrations in their treatment journey for migraine. [WATCH TIME: 5 minutes]
Understanding the Therapeutic Potential of Nipocalimab: Katie Abouzahr, MD
May 6th 2024The vice president, Autoantibody Portfolio and Maternal Fetal Immunology Disease Area Leader, Johnson & Johnson, provided perspective on the unique molecular structure of nipocalimab seen across nonclinical and clinical studies. [WATCH TIME: 3 minutes]